AP623A - Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents. - Google Patents
Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents. Download PDFInfo
- Publication number
- AP623A AP623A APAP/P/1996/000803A AP9600803A AP623A AP 623 A AP623 A AP 623A AP 9600803 A AP9600803 A AP 9600803A AP 623 A AP623 A AP 623A
- Authority
- AP
- ARIPO
- Prior art keywords
- alkyl
- mono
- chloro
- compound
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB1995/000442 WO1996039384A1 (en) | 1995-06-06 | 1995-06-06 | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
AP9600803A0 AP9600803A0 (en) | 1996-04-30 |
AP623A true AP623A (en) | 1997-12-19 |
Family
ID=11004338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/1996/000803A AP623A (en) | 1995-06-06 | 1996-04-25 | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents. |
Country Status (37)
Country | Link |
---|---|
US (1) | US6107329A (bg) |
EP (1) | EP0832065B1 (bg) |
JP (1) | JP3314938B2 (bg) |
KR (1) | KR100191992B1 (bg) |
CN (2) | CN1142492A (bg) |
AP (1) | AP623A (bg) |
AR (1) | AR003955A1 (bg) |
AT (1) | ATE206702T1 (bg) |
AU (1) | AU701465B2 (bg) |
BG (1) | BG100547A (bg) |
BR (1) | BR9602542A (bg) |
CA (2) | CA2224062C (bg) |
CO (1) | CO4700440A1 (bg) |
CZ (1) | CZ157396A3 (bg) |
DE (1) | DE69523182T2 (bg) |
DK (1) | DK0832065T3 (bg) |
FI (1) | FI974436A (bg) |
HR (1) | HRP960244A2 (bg) |
HU (1) | HUP9601475A2 (bg) |
IL (1) | IL118029A0 (bg) |
IS (1) | IS4341A (bg) |
LV (1) | LV11613B (bg) |
MA (1) | MA23866A1 (bg) |
MX (1) | MX9709875A (bg) |
NO (2) | NO306398B1 (bg) |
NZ (1) | NZ286460A (bg) |
OA (1) | OA10581A (bg) |
PL (1) | PL314561A1 (bg) |
RU (1) | RU2143424C1 (bg) |
SG (1) | SG44947A1 (bg) |
SI (1) | SI9600177A (bg) |
SK (1) | SK69996A3 (bg) |
TN (1) | TNSN96072A1 (bg) |
TR (1) | TR199600456A2 (bg) |
TW (1) | TW346485B (bg) |
WO (1) | WO1996039384A1 (bg) |
YU (1) | YU34896A (bg) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9709875A (es) * | 1995-06-06 | 1998-03-31 | Pfizer | N-(indol-2-carbonil)-glicinamidas substituidas y derivados como inhibidores de glicogeno fosforilasa, composiciones que las contienen y uso de las mismas. |
GB9601724D0 (en) * | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US5952322A (en) * | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
PL201487B1 (pl) | 1997-04-15 | 2009-04-30 | Csir | Sposób wytwarzania ekstraktu roślinnego, ekstrakt roślinny, środek o czynności hamowania łaknienia i zastosowanie ekstraktu roślinnego |
UA57811C2 (uk) * | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
EP0978279A1 (en) * | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
US6284725B1 (en) * | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
US7259136B2 (en) * | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
EP1147214B1 (en) | 1999-01-13 | 2011-01-05 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
EP1159273A1 (en) | 1999-03-02 | 2001-12-05 | Boehringer Ingelheim Pharmaceuticals Inc. | Compounds useful as reversible inhibitors of cathepsin s |
US6316489B1 (en) | 1999-03-15 | 2001-11-13 | Novo Nordisk A/S | Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine |
US6239163B1 (en) | 1999-03-15 | 2001-05-29 | Novo Nordisk A/S | Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine |
US6410750B1 (en) * | 1999-06-18 | 2002-06-25 | Pfizer Inc. | Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid |
US6107317A (en) * | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
US20060160740A1 (en) * | 1999-10-21 | 2006-07-20 | Suad Efendic | Use of GLP-1 or analogs in treatment of stroke |
GB2355657B (en) | 1999-10-27 | 2004-07-28 | Phytopharm Plc | Inhibitors Of Gastric Acid Secretion |
CN1414958A (zh) | 1999-11-04 | 2003-04-30 | 奥索-麦克尼尔药品公司 | 作为血管升压素拮抗剂的非肽、取代的苯并硫氮杂䓬 |
DK1741447T3 (da) | 2000-01-21 | 2013-12-09 | Novartis Ag | Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler |
CO5271699A1 (es) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
PE20011184A1 (es) * | 2000-03-16 | 2001-11-15 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
EP1136071A3 (en) * | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
JPWO2001085693A1 (ja) * | 2000-05-11 | 2004-01-08 | 萬有製薬株式会社 | N−アシルテトラヒドロイソキノリン誘導体 |
GB2363985B (en) | 2000-06-30 | 2004-09-29 | Phytopharm Plc | Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use |
IL144507A0 (en) * | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
AU775663B2 (en) | 2000-10-20 | 2004-08-12 | Amylin Pharmaceuticals, Inc. | Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide |
US7071181B2 (en) * | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
ATE308537T1 (de) | 2001-05-10 | 2005-11-15 | Solvay Pharm Gmbh | Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
EP1444204A4 (en) | 2001-10-22 | 2009-11-04 | Univ New York State Res Found | INHIBITORS OF PROTEIN KINASES AND PROTEINS PHOSPHATASES, METHODS OF IDENTIFICATION AND METHODS OF USE THEREOF |
JPWO2003037864A1 (ja) * | 2001-10-29 | 2005-02-17 | 日本たばこ産業株式会社 | インドール化合物及びその医薬用途 |
FR2834214B1 (fr) * | 2001-12-28 | 2004-09-24 | Lipha | Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete |
MXPA04006937A (es) * | 2002-01-18 | 2004-12-06 | Pfizer Prod Inc | Intermedios para la preparacion de inhibidores de la glucogeno fosforilasa. |
MXPA03000966A (es) | 2002-02-28 | 2003-09-04 | Pfizer Prod Inc | Agentes antidiabeticos. |
GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
US6683106B2 (en) | 2002-04-15 | 2004-01-27 | Pfizer Inc. | N-(indole-2-carbonyl)-b-alaninamide crystal forms |
JPWO2003091213A1 (ja) * | 2002-04-25 | 2005-09-02 | アステラス製薬株式会社 | 新規なアミド誘導体又はその塩 |
US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
US6960610B2 (en) | 2002-10-28 | 2005-11-01 | Novo Nordick, A/S | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
MXPA05004968A (es) * | 2002-11-07 | 2005-08-02 | Pfizer Prod Inc | N-(indol-z-carbonil)amidas como agentes anti-diabeticos. |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
US7705016B2 (en) * | 2003-02-13 | 2010-04-27 | Albert Einstein College Of Medicine Of Yeshiva University | Regulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamus |
US20040180845A1 (en) * | 2003-03-13 | 2004-09-16 | Newgard Christopher B. | Methods and compositions for modulating glycogen synthesis and breakdown |
US7595403B2 (en) | 2003-04-01 | 2009-09-29 | Eli Lilly And Company | Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors |
EP1620427A1 (en) * | 2003-04-17 | 2006-02-01 | Pfizer Products Inc. | Carboxamide derivatives as anti-diabetic agents |
EP1633709A1 (en) * | 2003-04-30 | 2006-03-15 | Pfizer Products Inc. | Anti-diabetic agents |
WO2004103958A2 (en) * | 2003-05-19 | 2004-12-02 | Michigan State University | Preparation of hymenialdisine derivatives and use thereof |
US7405210B2 (en) * | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
EA009215B1 (ru) * | 2003-05-21 | 2007-12-28 | Прозидион Лимитед | Ингибиторы гликогенфосфорилазы, представляющие собой амиды пирролопиридин-2-карбоновых кислот |
WO2004108671A1 (en) * | 2003-06-06 | 2004-12-16 | Suven Life Sciences Limited | Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them |
CN1809544A (zh) * | 2003-06-17 | 2006-07-26 | 麦克公司 | 作为二肽基肽酶抑制剂用于治疗或预防糖尿病的环己基甘氨酸衍生物 |
US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
PL1689757T3 (pl) | 2003-11-12 | 2015-05-29 | Sino Med Int Alliance Inc | Heterocykliczne związki kwasu boronowego |
US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
DE602005023965D1 (de) | 2004-03-08 | 2010-11-18 | Prosidion Ltd | Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
CA2573848A1 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Constrained cyano compounds |
US7884079B2 (en) * | 2004-12-27 | 2011-02-08 | Miller Landon C G | 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders |
US7226942B2 (en) | 2004-11-15 | 2007-06-05 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
WO2006055463A2 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
WO2006053274A2 (en) | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
GB0425919D0 (en) * | 2004-11-25 | 2004-12-29 | Prosidion Ltd | Indole-2-carboxylic acid amides |
WO2006059163A1 (en) * | 2004-12-02 | 2006-06-08 | Prosidion Limited | Treatment of diabetes with glycogen phosphorylase inhibitors |
EP1819332B1 (en) | 2004-12-02 | 2009-03-11 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amides |
US8691835B2 (en) | 2004-12-27 | 2014-04-08 | Landon C. G. Miller | 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders |
BRPI0609464A2 (pt) * | 2005-05-23 | 2010-04-13 | Japan Tobacco Inc | composto de pirazol e agente terapêutico para diabetes compreendendo o mesmo |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
HRP20140091T4 (hr) | 2005-09-14 | 2021-12-24 | Takeda Pharmaceutical Company Limited | Davanje inhibitora dipeptidil peptidaze |
CN100519524C (zh) * | 2005-09-29 | 2009-07-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚丙烯酸衍生物及其用于制备免疫抑制剂的用途 |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
AU2007297013B2 (en) * | 2006-09-13 | 2012-05-31 | Sanofi-Aventis | Isoserine derivatives for use as coagulation factor IXa inhibitors |
EP2096111A1 (en) * | 2006-11-20 | 2009-09-02 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
JP5498168B2 (ja) | 2006-12-01 | 2014-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体 |
MX2009006617A (es) * | 2006-12-18 | 2009-07-24 | Ambrx Inc | Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales. |
EP2368560A1 (en) | 2007-03-12 | 2011-09-28 | Zadec ApS | An anti-diabetic extract of rooibos |
CN101279955B (zh) * | 2007-04-03 | 2012-11-28 | 北京摩力克科技有限公司 | 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途 |
AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
PT2294066E (pt) | 2008-04-28 | 2014-11-21 | Janssen Pharmaceutica Nv | Benzoimidazoles como inibidores da prolil-hidroxilase |
AR072559A1 (es) * | 2008-07-15 | 2010-09-08 | Novartis Ag | Amidas sustituidas, composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades mediadas por dgat1. |
WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
CN102834393B (zh) | 2010-02-03 | 2015-07-22 | 武田药品工业株式会社 | 细胞凋亡信号调节激酶1抑制剂 |
WO2011145022A1 (en) | 2010-05-21 | 2011-11-24 | Pfizer Inc. | 2-phenyl benzoylamides |
CN102453001B (zh) * | 2010-10-22 | 2016-06-01 | 中国医学科学院药物研究所 | 硫代吗啉类化合物及其制备方法和用途 |
WO2012099785A2 (en) * | 2011-01-20 | 2012-07-26 | The Regents Of The University Of Colorado, A Body Corporate | Modulators of tlr3/dsrna complex and uses thereof |
EP2680874A2 (en) | 2011-03-04 | 2014-01-08 | Pfizer Inc | Edn3-like peptides and uses thereof |
ES2699773T3 (es) * | 2011-05-31 | 2019-02-12 | Theravance Biopharma R&D Ip Llc | Inhibidores de neprilisina |
AU2012328763A1 (en) | 2011-10-25 | 2014-05-01 | Janssen Pharmaceutica Nv | Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo(d)imidazol-2-yl)-1H-pyrazole-4-carboxylic acid |
MY188344A (en) | 2012-03-09 | 2021-12-01 | Biotropics Malaysia Berhad | Extract formulations of rhodamnia cinerea and uses thereof |
WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
CN103497181B (zh) | 2013-09-30 | 2016-03-30 | 承德医学院 | 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途 |
WO2015131113A1 (en) * | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
CN108329330B (zh) * | 2017-01-20 | 2021-05-04 | 复旦大学 | 2-苄氧苯基噁唑并吡啶类化合物及其药物用途 |
CN108191845A (zh) * | 2018-02-12 | 2018-06-22 | 李化绪 | 一种异恶唑亚氨基类化合物及其在降血脂药物中的应用 |
JOP20210193A1 (ar) | 2019-01-18 | 2023-01-30 | Astrazeneca Ab | مثبطات pcsk9 وطرق استخدامها |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039384A1 (en) * | 1995-06-06 | 1996-12-12 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4836846A (en) * | 1981-07-16 | 1989-06-06 | E. I. Du Pont De Nemours And Company | Herbicidal indole sulfonamides |
US4764610A (en) * | 1981-07-16 | 1988-08-16 | E. I. Du Pont De Nemours And Company | Herbicidal indole sulfonamides |
NZ202232A (en) * | 1981-11-06 | 1985-08-16 | Smithkline Beckman Corp | N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions |
US4933325A (en) * | 1985-08-14 | 1990-06-12 | G. D. Searle & Co. | Pyridyl and pyrimidinyl substituted tyrosyl dipeptide amides |
US4757151A (en) * | 1985-11-14 | 1988-07-12 | Warner-Lambert Company | 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl] |
US4902708A (en) * | 1985-12-31 | 1990-02-20 | Biomeasure, Inc. | CCK antagonists |
US5089638A (en) * | 1986-06-16 | 1992-02-18 | Merck & Co., Inc. | Amino acid analogs as CCK-antagonists |
HU204285B (en) * | 1986-10-31 | 1991-12-30 | Pfizer | Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them |
US5034376A (en) * | 1986-10-31 | 1991-07-23 | Pfizer Inc. | Nor-statine and nor-cyclostatine polypeptides |
MY103189A (en) * | 1986-10-31 | 1993-05-29 | Pfizer | Nor-statine and nor-cyclostatine polypeptides |
US5095004A (en) * | 1987-03-25 | 1992-03-10 | Bio-Mega Inc. | Fluorine containing atrial natriuretic peptides |
EP0288965A2 (de) * | 1987-04-29 | 1988-11-02 | Hoechst Aktiengesellschaft | Peptide mit Phospholipase A2- hemmender Wirkung |
US5128346A (en) * | 1987-09-21 | 1992-07-07 | Abbott Laboratories | Derivatives of D-glutamic acid and D-aspartic acid |
US5250517A (en) * | 1987-10-06 | 1993-10-05 | Hoffmann-La Roche Inc. | Renin inhibiting compounds |
EP0442878A4 (en) * | 1988-04-05 | 1991-10-23 | Abbott Laboratories | Derivatives of tryptophan as cck antagonists |
US5346907A (en) * | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
GB8810203D0 (en) * | 1988-04-29 | 1988-06-02 | Ici Plc | Heterocyclic compounds |
US4904846A (en) * | 1988-04-29 | 1990-02-27 | Augustin Oscadal | Oil filled body heater |
US5010089A (en) * | 1988-08-12 | 1991-04-23 | Biomeasure, Inc. | CCK antagonists and their use in treating gastrointestinal disorders |
FR2643371B1 (fr) * | 1989-02-17 | 1993-11-05 | Roussel Uclaf | Nouveaux derives de l'acide 2-amino pentanedioique, leur procede de preparation et leur application comme medicaments |
US4997950A (en) * | 1989-04-20 | 1991-03-05 | Richard Finbar Murphy | Novel C-terminal gastrin antagonists |
IE902238A1 (en) * | 1989-06-30 | 1991-01-16 | Abbott Lab | Tetrapeptide type-b cck receptor ligands |
IE902295A1 (en) * | 1989-07-07 | 1991-01-16 | Abbott Lab | Amino acid analog cck antagonists |
ATE118207T1 (de) * | 1989-12-04 | 1995-02-15 | Searle & Co | Heterozyklische acylaminodiol-beta-aminosäure- derivate. |
CA2072981A1 (fr) * | 1990-02-09 | 1991-08-10 | Jean-Dominique Bourzat | N-phenyl n-acetamido glycinamides, leur preparation et les medicaments les contenant |
CA2074357A1 (fr) * | 1990-03-07 | 1991-09-08 | Jean-Dominique Bourzat | Derives de glycinamide, leur preparation et les medicaments les contenant |
JPH03294253A (ja) * | 1990-04-12 | 1991-12-25 | Shionogi & Co Ltd | 消化管ホルモン拮抗物質 |
FR2674522B1 (fr) * | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
DE4115468A1 (de) * | 1991-05-11 | 1992-11-12 | Behringwerke Ag | Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien |
GB9206757D0 (en) * | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
WO1994006755A1 (en) * | 1992-09-18 | 1994-03-31 | Japan Tobacco Inc. | Alcohol derivative having renin-inhibiting activity and use thereof |
WO1994007815A2 (en) * | 1992-09-25 | 1994-04-14 | Abbott Laboratories | Small peptide anaphylatoxin receptor ligands |
AU675981B2 (en) * | 1992-12-02 | 1997-02-27 | Bristol-Myers Squibb Company | Guanidinyl-substituted heterocyclic thrombin inhibitors |
GB9309422D0 (en) * | 1993-05-07 | 1993-06-23 | Res Inst Medicine Chem | Chemical compounds |
AU2790895A (en) * | 1994-06-10 | 1996-01-05 | Universitaire Instelling Antwerpen | Purification of serine protease and synthetic inhibitors thereof |
-
1995
- 1995-06-06 MX MX9709875A patent/MX9709875A/es not_active IP Right Cessation
- 1995-06-06 AT AT95918717T patent/ATE206702T1/de not_active IP Right Cessation
- 1995-06-06 EP EP95918717A patent/EP0832065B1/en not_active Expired - Lifetime
- 1995-06-06 CA CA002224062A patent/CA2224062C/en not_active Expired - Fee Related
- 1995-06-06 CA CA002342471A patent/CA2342471C/en not_active Expired - Fee Related
- 1995-06-06 DE DE69523182T patent/DE69523182T2/de not_active Expired - Fee Related
- 1995-06-06 DK DK95918717T patent/DK0832065T3/da active
- 1995-06-06 US US08/952,669 patent/US6107329A/en not_active Expired - Fee Related
- 1995-06-06 WO PCT/IB1995/000442 patent/WO1996039384A1/en active IP Right Grant
- 1995-06-06 JP JP50024497A patent/JP3314938B2/ja not_active Expired - Fee Related
-
1996
- 1996-04-24 IS IS4341A patent/IS4341A/is unknown
- 1996-04-25 AP APAP/P/1996/000803A patent/AP623A/en active
- 1996-04-25 IL IL11802996A patent/IL118029A0/xx unknown
- 1996-04-25 NO NO961664A patent/NO306398B1/no unknown
- 1996-04-26 BG BG100547A patent/BG100547A/bg unknown
- 1996-04-26 NZ NZ286460A patent/NZ286460A/en unknown
- 1996-05-08 AR ARP960102762A patent/AR003955A1/es unknown
- 1996-05-13 MA MA24233A patent/MA23866A1/fr unknown
- 1996-05-17 TN TNTNSN96072A patent/TNSN96072A1/fr unknown
- 1996-05-28 SG SG1996009907A patent/SG44947A1/en unknown
- 1996-05-29 HR HRPCT/IB95/00442A patent/HRP960244A2/hr not_active Application Discontinuation
- 1996-05-30 CN CN96107768A patent/CN1142492A/zh active Pending
- 1996-05-30 BR BR9602542A patent/BR9602542A/pt not_active Application Discontinuation
- 1996-05-30 RU RU96110402A patent/RU2143424C1/ru active
- 1996-05-30 SI SI9600177A patent/SI9600177A/sl unknown
- 1996-05-30 AU AU54626/96A patent/AU701465B2/en not_active Ceased
- 1996-05-30 CZ CZ961573A patent/CZ157396A3/cs unknown
- 1996-05-31 OA OA60832A patent/OA10581A/en unknown
- 1996-05-31 TR TR96/00456A patent/TR199600456A2/xx unknown
- 1996-05-31 PL PL96314561A patent/PL314561A1/xx unknown
- 1996-05-31 KR KR1019960019379A patent/KR100191992B1/ko not_active IP Right Cessation
- 1996-05-31 SK SK699-96A patent/SK69996A3/sk unknown
- 1996-05-31 HU HU9601475A patent/HUP9601475A2/hu unknown
- 1996-05-31 LV LVP-96-165A patent/LV11613B/en unknown
- 1996-06-05 CN CN96107986A patent/CN1098838C/zh not_active Expired - Fee Related
- 1996-06-05 CO CO96029225A patent/CO4700440A1/es unknown
- 1996-06-05 YU YU34896A patent/YU34896A/sh unknown
- 1996-06-19 TW TW085107432A patent/TW346485B/zh active
-
1997
- 1997-12-05 FI FI974436A patent/FI974436A/fi not_active Application Discontinuation
-
1999
- 1999-01-28 NO NO990405A patent/NO990405D0/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039384A1 (en) * | 1995-06-06 | 1996-12-12 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP623A (en) | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents. | |
CA2223625C (en) | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | |
US6277877B1 (en) | Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors | |
AU2004276311A1 (en) | Substituted pyrrole-indoles as inhibitors of PAI-1 | |
EP1134213B1 (en) | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | |
US6846820B2 (en) | Substituted N-(indole-2-carbonyl) -amides and derivatives as glycogen phosphorylase inhibitors | |
DE69534574T2 (de) | Verfahren zur Herstellung von substituierten N-(Indol-2-carbonyl)-glycinamiden |